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Low expression of the 
PPARγ‑regulated gene 
thioredoxin‑interacting protein 
accompanies human melanoma 
progression and promotes 
experimental lung metastases
Patrick Meylan1, Christine Pich1,3, Carine Winkler1, Stefanie Ginster1, Lionel Mury1, 
Marie Sgandurra1,4, René Dreos1, Dennie Tompers Frederick2, Marc Hammond2, 
Genevieve Marie Boland2 & Liliane Michalik1* 
The thioredoxin system plays key roles in regulating cancer cell malignancy. Here we identify the 
Thioredoxin‑interacting protein (TXNIP) as a gene, which expression is regulated by PPARγ in 
melanoma cells. We show that high TXNIP expression levels associate with benign melanocytic 
lesions, with tumor regression in patients on MAP kinase targeted therapy, with decreased 
proliferation in patients’ melanoma biopsies, and with cell cycle arrest in human melanoma cell 
lines. In contrast, reduced TXNIP expression associates with advanced melanoma and with disease 
progression in patients. TXNIP depletion in human melanoma cells altered the expression of integrin 
beta‑3 and the localization of the integrin alpha‑v/beta‑3 dimer at their surface. Moreover, TXNIP 
depletion affected human melanoma cell motility and improved their capacity to colonize mouse 
lungs in an in vivo assay. This study establishes TXNIP as a PPARγ‑regulated gene in melanoma cells, 
thereby suggesting a link between these two proteins both involved in the regulation of cancer and 
of energy metabolism. It also reveals that the decrease in TXNIP expression, which is observed in 
advanced patient tumors, likely favors lung metastatic seeding of malignant cells.
Abbreviations
BMN  Benign melanocytic nevus
ECM  Extracellular matrix
GO  Gene ontology
MM  Metastatic melanoma
PM  Primary melanoma
ROS  Reactive oxygen species
TXNIP  Thioredoxin-interacting protein
Dissemination of malignant cells to distant organs is a lethal determinant in many cancers, including melanoma. 
Although much less frequent than skin basal-cell and squamous-cell carcinomas, skin melanoma remains the 
most aggressive form of skin cancers, responsible for 80% of skin cancer-related deaths, with incidence and 
associated mortality rates constantly  increasing1. Although the landscape of metastatic melanoma treatment 
has dramatically changed over the past few years with the development of immuno- and molecularly targeted 
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therapies, metastatic melanoma remains a tumor of dismal  prognosis2,3. Therefore, it remains of critical impor-
tance to unearth the molecular mechanisms underlying melanoma progression and dissemination, not only 
to better understand the behavior of this tumor, but also to identify novel prognostic markers or targets with 
preventive or therapeutic potential.
The PPARγ nuclear hormone receptor is best known as a key regulator of energy metabolism and as the best-
characterized molecular target of the insulin sensitizer drugs  thiazolidinediones4. In addition, several studies have 
described beneficial roles of PPARγ agonists in melanoma cells through inhibition of proliferation, or activation 
of apoptosis and/or  differentiation5,6. Pro-tumorigenic paracrine action of the PPARγ agonist rosiglitazone (RGZ) 
in melanoma has been reported,  however7,8, showing that PPARγ activation results in complex and context-
dependent outcomes, the molecular bases of which remain poorly characterized.
Thioredoxin-interacting protein (TXNIP, also named thioredoxin-binding protein 2 [TBP2] or vitamin D3 
upregulated protein 1 [VDUP1]) is a ubiquitously expressed protein initially described as an endogenous inhibi-
tor of thioredoxin expression and activity, which thereby counteracts thioredoxin protective role against oxida-
tive  stress9. Subsequently, TXNIP appeared to be a multifunctional protein, which has attracted attention as a 
regulator of lipid and glucose  metabolism10–12. Several lines of evidence also suggest that the loss of TXNIP is 
involved in the progression of bladder and hepatocellular  carcinoma13, while higher TXNIP levels are associated 
with a better prognosis in breast and gastric cancers, as well as in diffuse large B cell  lymphoma14–16. While the 
last few years have provided considerable knowledge of TXNIP roles in the regulation of energy metabolism and 
associated pathologies, less is known regarding TXNIP contribution to the development of cancers.
The present study aims to elucidate TXNIP functions in human melanoma. Using bioinformatics analyses of 
public data, cell culture and in vivo models, we identify TXNIP as a PPARγ-regulated gene, the downregulation 
of which during melanoma progression likely contributes to malignant cell seeding to distant organs.
Results
The expression of TXNIP is regulated by PPARγ. We first identified TXNIP as a PPARγ-regulated 
gene in a RNA-seq transcriptomic analysis of A375 human metastatic melanoma cell line described  in7 (Primary 
data accession number: GSE115221). Briefly, A375 cells, which express high levels of PPARγ and exhibit the 
typical BRAFV600E mutations found in approximately 50% of patient  tumors2,17, were treated with the PPARγ 
agonist Rosiglitazone (RGZ), the PPARγ antagonist T0070907 or a combination of both, in order to discriminate 
between true PPARγ-regulated genes and off-target effects of RGZ. Only the genes significantly deregulated by 
RGZ but not by RGZ in combination with T0070907 were considered as bona fide PPARγ-regulated genes and 
selected for further analysis. With this approach, we found that TXNIP expression was downregulated by PPARγ 
activation in A375 metastatic melanoma cells (absolute fold change −1.36; False discovery rate 0.031;7). We then 
validated PPARγ-dependent regulation of TXNIP with several independent approaches, using CPT1A or FABP4 
canonical targets as readouts for PPARγ activity. As expected for bona fide PPARγ-regulated genes, TXNIP 
downregulation and CPT1A upregulation by RGZ were both prevented by cotreatment with the selective PPARγ 
antagonist T0070907 (Fig. 1A), and the regulation of TXNIP and FABP4 was prevented by siRNA-mediated 
down-regulation of PPARγ (Fig. 1B). As a further evidence, we found that the non-thiazolidinedione PPARγ 
Figure 1.  TXNIP is a PPARγ-regulated gene. (A) RT-qPCR analysis of TXNIP and CPT1A mRNA expression 
in A375 cells after a 24 h treatment with 5 μM of the PPARγ agonist RGZ, with 2 μM of the PPARγ antagonist 
T0070907 or both. House-keeping genes: YWHAZ and B2M. Each open circle represents one experiment with 
biological triplicates (n = 3). Columns are means of three independent experiments (N = 3). Statistics: one-way 
ANOVA with Dunnett’s multiple comparison test (B) RT-qPCR analysis of PPARG , FABP4, and TXNIP mRNA 
expression in A375 cells transfected with control (siCtl) or siPPARG siRNA, treated or not with 5 μM of the 
PPARγ agonist RGZ for 24 h, as indicated. House-keeping genes: YWHAZ and B2M. Each open circle represents 
one experiment with biological triplicates (n = 3). Columns are means of three to four independent experiments 
(N = 3–4). Statistics: unpaired Student’s t-test (C) RT-qPCR analysis of TXNIP and CPT1A mRNA expression 
in A375 cells after a 24 h treatment with increasing concentrations of the non-TZD PPARγ agonist GW1929. 
House-keeping genes: YWHAZ and B2M. Columns are means of biological duplicates (n = 2) of one experiment 
(N = 1) ± SD. (D) RT-qPCR analysis of TXNIP, CPT1A, FABP4 mRNA expression in A375 cells after 2, 4, 6 and 
24 h of 5 μM RGZ treatment, then 24 h, 48 h and 72 h after RGZ removal. House-keeping genes: YWHAZ and 
B2M. One time course experiment was performed (N = 1). Columns represent the means of technical replicates. 
(E) RT-qPCR analysis of TXNIP mRNA expression in normal human melanocytes (NHM) and in human 
melanoma cell lines WM35 (radial-growth phase), WM115 (vertical-growth phase), SK-MEL-28 (metastatic), 
and WM793 (metastatic) after a 24 h treatment with 5 μM RGZ. House-keeping genes: NHM: TBP and B2M; 
WM35: YWHAZ and HPRT; WM115: TBP and HPRT; SK-MEL-28: YWHAZ and TFRC; WM793: YWHAZ. 
Each open circle represents one experiment with biological triplicates (n = 3). Columns are means of three 
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agonist GW1929 also downregulated TXNIP and upregulated CPT1A in a dose-dependent manner, ruling out 
RGZ-specific regulation of TXNIP expression (Fig. 1C). A kinetic study showed that TXNIP mRNA expression 
was modulated as early as 2 h after RGZ addition and that it quickly returned to basal values upon ligand clear-
ance (Fig. 1D, left panel), a kinetic also observed for CPT1A and FABP4 (Fig. 1D, middle and right panels), two 
canonical direct PPARγ target genes. Finally, downregulation of TXNIP expression levels by RGZ was not spe-
cific to the A375 metastatic cells, as it was also observed in the human melanoma cell lines WM35 (radial-growth 
phase), WM115 (vertical-growth phase), SK-MEL-28 (metastatic) and WM793 (metastatic) human melanoma 
cells (Fig. 1E). In contrast, RGZ treatment had little impact on TXNIP expression in healthy primary human 
melanocytes (NHM, Fig. 1E).
Low TXNIP expression associates with advanced melanocytic lesions, tumor progression, and 
higher proliferation in patients’ melanoma biopsies. Several studies have reported roles of PPARγ 
and its agonists in melanoma cells using in vitro and in vivo  approaches5 but have in most cases not addressed 
the mechanisms involved. We thus sought to assess what contribution could TXNIP make to the roles played 
by PPARγ and its agonists in melanoma cells. As a first approach to a better understanding of TXNIP functions 
in melanoma, we quantified its expression in metastatic melanoma of commercially available melanoma cDNA 
arrays, as well as in two publicly available NCBI GEO microarray datasets (GSE46517 and GSE3189, chosen 
for high sample numbers and unequivocal experimental design) of benign melanocytic nevi (BMN), primary 
(PM) or metastatic (MM) melanomas. We found that TXNIP RNA levels were six times lower in melanoma as 
in healthy control samples (Fig. 2A), and also significantly downregulated in malignant (PM or MM) versus 
benign (BMN) lesions in the two microarray datasets analyzed (Fig. 2B,C; Supp. Figure 1A). We next addressed 
whether variations in TXNIP expression levels were associated with disease stabilization or regression upon 
MAP kinase targeted therapy. We used RNA-seq data from a unique set of patient metastases’ biopsies that have 
been acquired longitudinally from patients with metastatic melanoma before (Pre-treatment) and during (On-
treatment)  MAP kinase targeted therapy, as well as treatment-resistant tumor biopsies (Treatment-resistant) 
(Table 1;18). Analysis of these data combined to RT-qPCR quantifications showed that On-treatment specimens 
expressed significantly higher levels of TXNIP compared to Pre-treatment specimens (Fig. 2D; Supp. Figure 1B). 
Interestingly, higher TXNIP expression levels in On-treatment specimens positively correlated with higher 
degree of tumor regression (RECIST, Response Evaluation Criteria in Solid Tumors; linear model, P = 0.00898; 
Fig. 2E). In the same patient specimen, we found an anti-correlation of TXNIP expression with the prolifera-
tion markers Cyclin B1 (CCNB1) and Cyclin D (CCND1) (Pearson correlation coefficient −0.456 and −0.502, 
respectively), and a correlation of TXNIP expression with the cell-cycle inhibitor pRb (RB1  ; retinoblastoma 
protein; Pearson correlation coefficient 0.356) (Fig. 2F). Along the same line, increased expression of TXNIP in 
On-treatment specimens was associated with decreased expression of the proliferation marker PCNA and lower 
proportion of Ki67-positive melanoma cells in 10 out of the 12 patient samples analyzed (Supp Fig. 1B–D).
TXNIP expression and melanoma cell cycle arrest or apoptosis. To substantiate the observation 
that higher TXNIP level was associated with decreased proliferation in metastatic melanoma biopsies, we ana-
lyzed the profile of TXNIP expression in proliferating and resting A375 cells, as well as in C8161 cells, a cutane-
ous metastatic melanoma cell line that also harbor an activating mutation of BRAF commonly found in patient 
 tumors17,19,20. A375 and C8161 cells were serum-deprived to provoke cell cycle arrest. Like in patient melano-
cytic lesions, we observed an increase of TXNIP expression, concomitantly with a downregulation of the prolif-
eration marker Cyclin D1 (A375, Fig. 3A,B) or an upregulation of the cell cycle inhibitor p21 (C8161, Fig. 3C,D). 
Moreover, we found that TXNIP was significantly upregulated at the mRNA and protein levels in A375 cells by a 
Figure 2.  Low TXNIP expression levels associate with advanced melanocytic lesions, with tumor progression, 
and with higher proliferation in patients’ melanoma biopsies. (A) RT-qPCR analysis of TXNIP mRNA 
expression in healthy controls and human metastatic melanomas stage III and stage IV. Open circles represent 
individual donors; grey triangle represents a pool of primary melanocytes isolated from several donors; lines 
represent means. House-keeping genes: TBP and YWHAZ. Statistics: one-way ANOVA with Dunnett’s multiple 
comparison test. (B) Expression of TXNIP (log2 scale) in a microarray dataset (GSE46517) comparing 7 benign 
melanocytic nevi (BMN), 8 primary melanomas (PM) and 57 metastatic melanomas (MM). Circles represent 
individual samples; lines represent means. Colors represent tumor staging according to the AJCC staging 
system (8th edition, 2014): orange : stage 1A; green : stage 1B; dark blue : stage 2A; red: stage 2B; pink: stage 
3B; burgundy: stage 3C; light blue: stage 4. Statistics: one-way ANOVA with Dunnett’s multiple comparison 
test. (C) Expression of TXNIP (log2 scale) in a microarray dataset (GSE 3189) comparing 18 BMN and 45 PM. 
Open circles represent individual samples; lines represent means. Statistics: unpaired Student’s t-test. (D) TXNIP 
expression values in Reads Per Kilobase of transcript per Million mapped reads (RPKM) stratified by tumor 
stages. Differences were analyzed using analysis of variance followed by Tukey test (p-value Pre-treatment versus 
On-treatment: 0.0014). (E) TXNIP expression values (RPKM) plotted against RECIST (Response Evaluation 
Criteria in Solid Tumors) scores stratified by tumor stage. Light grey circle: Pre-treatment; medium grey 
triangle: On-treatment; dark grey square: Treatment-resistant. Lines represent the regression analyses evaluated 
using linear models. A statistically significant coefficient was found for On-treatment samples (P = 0.0089). (F) 
Correlation analysis between TXNIP expression values (RPKM) and Cyclin B1 (CCNB1), Cyclin D (CCND1) 
and pRb (RB1). Correlation coefficient (R) is plotted in the top right corner, whereas regression lines calculated 
with liner models are plotted in blue (coefficients’ p-values: CCNB1 = 0.0035; CCND1 = 0.00112; RB1 = 0.0262). 
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wide range of drugs known to have strong anti-proliferative activity via diverse mechanisms (Fig. 3E,F). Of note, 
the increase in TXNIP expression observed in A375 upon treatment with the MAP kinase pathway inhibitors 
(Fig. 3E,F) is in line with the increase in TXNIP expression that we uncovered in patients under MAP kinase 
targeted therapy (Fig. 2D; Table 1).
We next mimicked the decreased TXNIP expression that seemingly occurs in the course of melanoma pro-
gression. We derived fluorescent A375 cells constitutively expressing an shRNA against TXNIP (A375-shTXNIP) 
or a random shRNA (A375-shScr) using lentiviral transduction. We selected a polyclonal A375-shTXNIP cell 
population exhibiting a 30% decrease in TXNIP expression at the RNA level, in line with the magnitude of TXNIP 
downregulation that occurs in malignant (PM or MM) versus benign (BMN) lesions (Fig. 2B,C; Supp Fig. 2A, 
RNA and protein levels, left and right panels, respectively). This decrease in TXNIP RNA was accompanied by 
a 20% decrease in TXNIP protein (Supp Fig. 2A, right panel). We found that neither proliferation nor apoptosis 
of A375 cells was affected by decreased TXNIP expression levels (Fig. S2B,C, and D).
A decrease in TXNIP expression alters the expression of genes involved in melanoma cell 
adhesion and in extracellular matrix remodeling. To shed light onto the potential roles of TXNIP 
in human melanoma cells, we performed an RNA-seq on A375 cells transiently transfected with TXNIP versus 
control siRNA (Supp Fig. 2E). Transient knockdown was chosen here to identify the direct effects of the TXNIP 
knockdown. With cut-off values for adjusted P-value and absolute fold change set at 0.05 and 2 respectively, we 
obtained 1438 significantly deregulated (1014 up- and 424 downregulated) genes (Fig. 4A; Table 2 for the top 
ten downregulated and upregulated genes). The two protein classes most significantly affected by TXNIP knock-
down were ligands (enrichment ratio = 1.9; P < 0.001) and receptors (1.7; P < 0.001) (Table S1). Gene ontology 
(GO) analyses were in line with this finding; the three most significant GO localizations were “Cell periphery”, 
“Plasma membrane” and “Plasma membrane part” (Table  S2), and the three most significant GO molecular 
functions were “Protein binding”, “Binding” and “Receptor binding” (Table S3). Interestingly, the three most 
significantly deregulated pathway maps included “Cell adhesion extracellular matrix remodeling” and “Develop-
ment and regulation of epithelial-to-mesenchymal transition” (Table S4). Moreover, several of the most deregu-
lated KEGG pathways were related to cell adhesion (Table S5), overall suggesting a potential role of TXNIP in 
melanoma cell dissemination.
We next selected a subset of significantly deregulated genes with functional annotations related to cell adhe-
sion and extracellular matrix (ECM) remodeling for further validation. This subset comprised three categories 
of genes: integrins, matrix metalloproteases (MMPs) and ECM components. For all the selected genes except 
MMP16, fold changes measured by RT-qPCR were tightly correlated (r = 0.94; P < 0.001) with those measured 
by RNA-seq (Fig. 4B–E). Among those actors of particular interest to melanoma metastasis, a strong increase 
in the expression of integrin beta-3 (ITGB3) and TIMP-2 was confirmed at the protein level in A375-shTXNIP 
versus A375-shScr human melanoma cells (Fig. 4F–G), while integrin alpha-11, collagen alpha3(VI), MMP-1 
and MMP-14 proteins remained unaffected (Supp Fig. 3A–D). A FACS analysis revealed that the increased 
expression of integrin beta-3 was associated with a significant upregulation of the integrin alpha-v/beta-3 dimer 
at the surface of A375-shTXNIP compared to A375-shScr cells (Fig. 4F, right panel). Integrin beta-3 expression 
level and alpha-v/beta-3 localization at the cell membrane were also affected upon shRNA-mediated TXNIP 
silencing in C8161 cells; in those cells, however, TXNIP silencing (Supp Fig. 3E) resulted in a downregulation 
of integrin beta-3 expression and alpha-v/beta-3 localization at the cell membrane, while TIMP2 expression 
remained unaffected (Fig. 4H–I).
Table 1.  Patient clinical informations. Biopsy day: date of biopsy-therapy start date, RECIST: best response 








2 Vemurafeniba −33 9 NA PR (‐60.5%)
6 Dab-rafeniba  +  Trametinibb −42 28 NA PR (‐59.9%)
8 Dab-rafeniba  +  Trametinibb −2 5 NA PR (‐30%)
10 Dab-rafeniba  +  Trametinibb 0 12 NA SD (−13%)
11 Dab-rafeniba  +  Trametinibb −3 6 NA PR (−80%)
12 Dab-rafeniba  +  Trametinibb 0 8 NA PR (−88.9%)
16 Dab-rafeniba  +  Trametinibb −9 7 335, off drug SD (−19.5%)
24 Vemurafeniba 0 7 266, on drug PR (−53%)
34 LGX818a +  MEK162b −4 16 487, off drug PR (−75.8%)
35 LGX818a +  MEK162b −1 21 707, off drug PR (−38.6%)
40 Vemurafeniba −5 10 NA PR (UN)
42 LGX818a +  MEK162b 0 27 496, off drug PR (−76.1%)
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TXNIP knockdown affects melanoma cell adhesion and impairs their migration. We next exam-
ined the functional impact of TXNIP-dependent regulation of genes involved in melanoma cell adhesion and 
migration—two critical processes for metastasis formation. TXNIP-dependent regulation of human melanoma 
cell adhesion was assessed using trypsin resistance assays as well as conventional adhesion assays. In the former, 
A375-shTXNIP cells demonstrated significantly more resistance to trypsin-mediated cell–matrix dissociation 
(Fig. 5A). In agreement with an active role of TXNIP in controlling melanoma cell adhesion, conventional adhe-
sion assays revealed enhanced adhesion of A375-shTXNIP cells on plates coated with fibronectin (Fig. 5B), while 
C8161-shTXNIP cells exhibited decreased adhesion on the same substrate (Fig. 5C). A375-shTXNIP cells also 
tended to display better adhesion than A375-shScr cells on vitronectin (Fig. 5B). Additionally, cell monolayer 
scraping (Fig. 5D,E) and transwell migration assays (Fig. 5F) revealed that A375-shTXNIP cells migrated signifi-
cantly less efficiently than A375-shScr cells. As described above (Supp Fig. 2), proliferation and apoptosis rates 
were not affected by TXNIP knockdown, ruling out any bias in the assessment of migration speed.
Decrease in TXNIP expression levels favor melanoma cell seeding to the lung. We next assessed 
the impact of TXNIP downregulation in melanoma cells in vivo using only A375 metastatic cells as a model 
in order to limit animal use. The above-described A375-shTXNIP or A375-shScr human melanoma cells were 
implanted subcutaneously in immunocompromised mice. In line with our observations that a decrease in 
TXNIP expression did not affect melanoma cell proliferation nor apoptosis, we found no correlation between 
TXNIP expression levels in the melanoma xenografts and their growth rate (Fig. 6A). We next addressed TXNIP 
role in melanoma cell seeding to distant organs by quantifying the ability of fluorescently-labelled TXNIP-defi-
cient A375 cells to establish lung tumors following injection into the tail vein of immunocompromised mice. 
Quantitative assessment of tumors of human-cell origin was performed by visual quantification of fluorescently 
labelled tumors in whole lungs (Fig. 6B). Quantification of fluorescence was complemented by an independ-
ent, RT-qPCR-based approached, in which we chose human B2M, MITF and MART-1 as human cell mark-
ers quantified over two murine housekeeping genes to detect human cell presence in mouse lungs (Fig. 6C). 
Human B2M was chosen as a gene expressed in all human cells, while human MITF and MART-1 were chosen 
as human melanocyte-lineage specific markers. Their expression was not significantly affected by TXNIP silenc-
ing in A375-shTXNIP cells, and amplification specificity of human B2M, MITF and MART-1 was first verified 
by the absence of amplification of these cDNA in normal lung tissue of non-injected mice (data not shown). We 
found that the lung metastatic load was greater in mice injected with A375-shTXNIP compared to A375-shScr 
cells, as shown by greater number of fluorescently labelled tumors quantified in whole lungs and greater average 
expression of human B2M and MITF in the lung of these animals (Fig. 6B,C, respectively). Although not statisti-
cally significant, the expression of MART-1 showed the same trend (Fig. 6C, right panel). TXNIP being known 
to play a role in melanoma cell intravasation via a redox-sensitive  mechanism21, we addressed whether the cell 
seeding-promoting role of low TXNIP expression relied on a modulation of melanoma cell ROS content. ROS-
sensitive fluorescence assays showed that knockdown of TXNIP did not affect  H2O2-induced oxidative stress in 
A375 cells (Fig. S3G).
Discussion
Our study reveals that a progressive decrease in TXNIP expression is associated with the progression of melanoma 
towards a metastatic phenotype, whereas high TXNIP expression level associates with tumor regression (RECIST) 
and with decreased proliferation in patients on MAP kinase targeted therapy. The contribution of TXNIP to the 
progression of melanoma is unknown, despite evidence of TXNIP-dependent regulation of proliferation, ROS 
levels and intravasation in mouse or human melanoma  cells21–23. Furthermore, the majority of studies of TXNIP 
roles in cancers have investigated the consequences of its  overexpression13, while interrogating the contribution 
of TXNIP downregulation to cancer progression has been neglected. Here we establish that TXNIP silencing 
in human melanoma cells—to an extent commensurate with the decrease observed in malignant versus benign 
lesions in patients—did not affect melanoma cell proliferation nor ROS levels but affected the expression of pro-
teins of particular relevance to melanoma cell invasiveness, integrin alpha-v/beta-3 and TIMP-2. Experimental 
and endogenous upregulation of integrin beta-3 expression indeed correlates with the malignant potential of 
human melanoma cells, with the transition from dysplastic nevi to invasive melanomas and with preferential 
metastatic seeding to the lung ; conversely, normal melanocytes or early-stage melanomas do not express inte-
grin beta-324,25. More particularly, the activation of integrin alpha-v/beta-3 dimer is a characteristic of invasive 
melanoma  cells26–30. Finally, TIMP-2 was shown to contribute to the activation of MMP-2 at the cell membrane 
in vitro and in vivo, and may thereby promote melanoma cell  invasiveness31,32.
We further demonstrate that changes in the expression of genes involved in melanoma cell invasiveness has 
functional consequences: it affects cell adhesive and migratory properties and favors experimental metastatic 
seeding in mouse lungs in vivo. Consistent with our findings are the previous observations that TXNIP artificial 
overexpression in human melanoma cells reduces metastatic seeding in the lung of athymic  mice23, and that 
miRNA-mediated TXNIP silencing in human breast cancer cells promotes metastasis  formation33. Although 
TXNIP may exert anti-cancer functions through a variety of mechanisms, such as inhibition of proliferation, 
promotion of apoptosis, or reduction of ROS  levels9,10, 13,34 our data indicate that in melanoma cells, decreased 
TXNIP expression may contribute to melanoma progression by promoting melanoma cell seeding to distant 
organs rather than fostering primary tumor growth.
On the basis of the beneficial impacts of its overexpression, TXNIP has been mentioned as potential thera-
peutic targets in  cancers13. Our study suggests that in melanoma, reactivation of TXNIP expression may be 
of interest to reduce malignant cell invasive capacities. There are, however, important limitations to consider 
regarding the activation of TXNIP. First, we show that the downregulation of TXNIP had opposite effects on 
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the expression of integrin alpha-v/beta-3 and TIMP-2 in two different human metastatic cell lines. This suggests 
context-dependent consequences in modulating TXNIP activity in melanoma, the characterization of which 
requires further investigation. Second, while activating TXNIP may be beneficial in cancer, data accumulated in 
the last few years strongly suggests that this would have a deleterious impact on lipid and glucose metabolism, 
with an increased risk of developing  diabetes11,12. Thus, developing TXNIP-targeted therapy should be restricted 
to cancers exhibiting TXNIP downregulation and should aim at normalizing but not at increasing TXNIP activity.
Our study is the first to link TXNIP to another therapeutic target, the nuclear hormone receptor PPARγ. 
PPARγ is indeed the best-characterized target of the insulin-sensitizers of the thiazolidinedione family used in the 
treatment of type 2 diabetes, and its use as a therapeutic anti-cancer target is also a matter of debate. While PPARγ 
activation was mostly reported to exhibit anticancer effects in a variety of cancer cells including  melanoma35, we 
have recently characterized a protumorigenic paracrine role of the PPARγ agonist RGZ in human  melanoma7,8. 
Here we reveal that PPARγ activation reduces the expression of TXNIP in human melanoma cells. Whether the 
regulation of TXNIP by PPARγ is direct (that is, by direct binding of PPARγ in its promoter) or indirect goes 
beyond the objectives of this study and would require further investigation. Nevertheless, while this adds to the 
potentially protumorigenic effects of activating PPARγ in melanoma, it also raises the intriguing possibility that 
decreasing the expression of TXNIP, which is currently considered a promising approach for treating type 2 
 diabetes11,12, could be involved in PPARγ and RGZ-antidiabetic actions.
Material and methods
Surgical specimens. All experimental protocols  involving surgical specimens were approved by ethics 
committees and research was performed in accordance with relevant regulations:
—Abdominal skin biopsies were obtained anonymously from the Department of Musculoskeletal Medicine 
Biobank, University Hospital of Lausanne, Switzerland. Informed consent for research was obtained prior to 
surgery and was regulated through the Department of Musculoskeletal Medicine Biobank (University Hospital of 
Lausanne, Switzerland, Profs. Raffoul and Applegate). The protocol was approved by the Canton de Vaud Ethics 
Committee on research involving humans (CER-VD).
—Serial melanoma metastases biopsies and clinical data were collected from patients with metastatic mela-
noma at the Division of Surgical Oncology, Massachusetts General Hospital, Boston, USA. All human subjects 
and associated materials were consented under the translational protocol approved by the Dana Farber/Harvard 
Cancer Center Institutional Review Board (IRB ; DFCI 11-181 ; PI: Boland).
Melanoma cDNA array (MERT501) containing ten identical sets of 43 tissues covering four disease stages 
(1 × Stage IIIA, 6 × IIIB, 4 × IIIC, 10 × III 19 × IV) and normal tissues was purchased from OriGene.
Cell culture and treatments. Human melanoma cell lines A375 (CLS Cat# 300110/p852_A-375, 
RRID:CVCL_0132) and C8161 (RRID:CVCL_6813; kindly provided by Prof. D. Constam, EPFL, Lausanne, 
Switzerland) were grown in DMEM supplemented with 10% FBS. Pooled human healthy primary melanocytes 
(ATCC) and primary melanocytes from individual donors (kindly provided by Prof. D. Fisher (Massachu-
setts General Hospital, Cutaneous Biology Research Center, Boston, USA) were grown in Melanocyte Growth 
Medium M2 supplemented with SupplementMix Melanocyte Growth Medium (PromoCell). All cultures were 
maintained at 37 °C in a 5%  CO2 humidified atmosphere, with medium renewal every 2 or 3 days.
A375 cells were treated during 24 h with PLX4032 (100 nM; Axon Medchem), U0126 (5 μM; New England 
Biolabs), suberoylanilide hydroxamic acid (5 μM), colchicine (100 nM), camptothecin (1 μM), dichloroacetate 
(50 mM) and sodium oxamate (10 mM) all from Sigma-Aldrich. The effect of each drug was normalized to its 
Figure 3.  TXNIP upregulation is associated with decreased proliferation in human melanoma cells. (A–C) 
RT-qPCR analysis of TXNIP, CCND1, PCNA and CDKN1A mRNA levels (log2 scale) in human melanoma 
cells (A) A375 or (C) C8161 after 24 h of serum deprivation. Each open circle represents one experiment with 
biological triplicates (n = 3). Columns are means of three independent experiments (N = 3). House-keeping 
genes: B2M (A) and YWHAZ (C). Statistics: unpaired Student’s t-test. (B–D) Left panels: western blot analysis 
of TXNIP, Cyclin D1, PCNA and p21 protein levels in human melanoma cells (B) A375 or (D) C8161 after 
24 h of serum deprivation. Actin or GAPDH were used as loading controls and were run on the same gel as the 
protein of interest. Cropped western blots are shown. Full-length western blots and densitometry are shown 
in Supplementary Figs. 4 and 5. Right panels: quantification of western blot shown on left panels. Columns 
are means of biological triplicates (n = 3) ± SD. (E) RT-qPCR analysis of TXNIP mRNA levels in human A375 
melanoma cells treated for 24 h with PLX4032 (BRAFV600E inhibitor; 100 nM), U0126 (MEK inhibitor; 
5 mM), SAHA (a histone deacetylase inhibitor; 5 mM), colchicine (a microtubule polymerization inhibitor, 
100 nM), CPT (camptothecin, a topoisomerase I inhibitor and anticancer compound; 1 mM), DCA and OXA 
(dichloroacetate; 50 mM and sodium oxamate; 10 mM, respectively, two inhibitors of the Warburg effect). 
The effect of each drug was normalized to its corresponding control; only one column is shown for controls, 
for the sake of simplicity. Each open circle represents one experiment with biological triplicates (n = 3). Three 
independent experiments were performed (N = 3) except for SAHA and OXA (N = 2). Columns are means of 
two to three independent experiments. House-keeping genes: YWHAZ and B2M. Statistics: one-way ANOVA 
with Dunnett’s multiple comparison test. (F) Top panel: western blot analysis of proteins extracted from human 
A375 melanoma cells treated for 48 h as in (E). Loading control (GAPDH) was run on the same gel. Cropped 
western blots are shown. Full-length western blot and densitometry are shown in Supplementary Fig. 6. Bottom 
panel: Quantification of the immunoblot shown in top panel (N = 1). Numbers represent fold changes to control 
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corresponding control: the vehicle for PLX4032, U0126, suberoylanilide hydroxamic acid and camptothecin was 
DMSO, used alone in control cells at a maximal concentration of 0.1% (vol/vol); an equimolar sodium chloride 
solution was used as a control for colchicine, dichloroacetic acid and sodium oxamate treatments.
TXNIP knockdown. siTXNIP transfection: 20–50% confluent A375 were transfected with predesigned 
27-mer siRNA duplexes (Origene) using Lipofectamine RNAiMAX (Life Technologies) as per manufacturer’s 
instructions, and incubated for 48 h at 37 °C. Scrambled siRNA (siControl) were used as controls.
shTXNIP transduction: A375 and C8161 were transduced with premade lentiviruses (GeneCopoeia) express-
ing TXNIP shRNA or scrambled control shRNA along with the mCherry fluorescent protein, using 5 μM poly-
brene (Sigma-Aldrich). 4 days later, medium supplemented with 1.25 μg/ml puromycin (InvivoGen) was added 
for at least 3 weeks for selection of transduced cells . No clonal selection was performed. Polyclonal batch cultures 
of A375-shTXNIP, A375-shScr, C8161-shTXNIP, C8161-shScr cells were checked for TXNIP expression levels 
by RT-qPCR and used for further experiments.
Cell functional assays. Cell cycle arrest was provoked by serum deprivation (DMEM 0% FBS) for 24 h.
Cell monolayer scraping assays: cell monolayers were wounded by scratching with a plastic cell scraper 
trimmed (1 mm width). Nine random locations (3 per well of a 6-well plate, 3 wells per condition) were chosen 
for each condition where pictures were taken at the time points indicated in the figures. Wound area was meas-
ured on each picture using ImageJ and the percent wound closure calculated.
Cell adhesion assays: for trypsin resistance assays, A375-shTXNIP and A375-shScr cells grown on uncoated 
24-well plates were washed with PBS and trypsinized for half the time normally required to detach all the cells. 
After washes, 50 μl RIPA was added to lyse the cells that were still attached. Wells where no trypsin was added 
were used to calculate the fraction of adhesive cells. For adhesion assays, 60 mm dishes were coated with colla-
gen I (48 μg/ml), collagen IV (33 μg/ml), fibronectin (10 μg/ml) all from Sigma-Aldrich or vitronectin (3 μ/ml ; 
Thermo Fischer Scientific). A375-shTXNIP, A375-shScr, C8161-shTXNIP, and C8161-shScr cells were plated 
in each dish and incubated at 37 °C for 45 min. After two washes with PBS, adhesive cells were trypsinized and 
counted, and the fraction of adhesive cells calculated.
Transwell migration assays: A375-shScr and A375-shTXNIP cells were plated on cell culture microporous 
membranes (8 μm pore size, 1.105 pores/cm2; Falcon/Brunschwig). They were then incubated at 37 °C / 5% 
 CO2 in DMEM 0%FBS for 6 h with DMEM 10% FBS in the bottom well as chemoattractant. Medium was then 
removed from the inserts and from the companion plate wells. Cells that had not migrated were removed from 
the top of the membranes. Cells at the bottom of the membrane and in the wells were fixed (ice-cold methanol 
100%; 10 min, RT) then stained with Crystal violet 0,5% for 10 min at RT. Cell quantification was performed 
using ImageJ.
Flow cytometry analysis of integrins. A375-shScr, A375-shTXNIP, C8161-shTXNIP, and C8161-shScr 
cells were collected with Hank’s based cell dissociation buffer (Life Technologies) and washed in PBS.
For integrin analysis, cells were stained with Alexa-Fluor 647 conjugated anti-integrin alpha-v/beta-3 mAb 
and isotope control (1:25 dilution, BioLegend Cat# 400130, RRID:AB_2800436) at 4 °C for 35 min, protected 
from light. Stained cells were analyzed on a Accuri C6 flow cytometer (BD Accuri C6 Plus, RRID:SCR_014422) 
and the results were analyzed with FlowJo software (RRID:SCR_008520). Percent of integrin alpha-v/beta-3 
positive A375-shTXNIP, A375-shScr, C8161-shTXNIP, and C8161-shScr cells were quantified.
Figure 4.  TXNIP knockdown affects the expression of genes involved in human melanoma cell adhesion and 
in extracellular matrix remodeling. (A) Overview of the pipeline used to analyze the RNA-seq of A375 cells 
under transient TXNIP knockdown. FC, fold change. (B) Spearman’s correlation plot comparing fold changes 
measured by RT-qPCR and by RNA-seq (analysis of three independent experiments, N = 3) for the panel of 
genes shown in (C–E) RT-qPCR analysis of TXNIP knockdown-induced changes in the mRNA expression of 
the genes selected for validation. Columns are means of two biological duplicates (n = 2) ± SD of one RT-qPCR 
quantification. House-keeping genes: YWHAZ and B2M. (F) Left panel: Western blot analysis of integrin beta-3 
levels in total proteins extracted from A375-shScr and A375-shTXNIP; vinculin (Vinc) was used as a loading 
control and was run on the same gel; biological triplicates (n = 3) from one experiment are shown. Cropped 
western blots are shown; full-length western blots and densitometry are shown in Supp. Figure 7. Right panel: 
Flow cytometry analysis of integrin alpha-v/beta-3 (Int av/b3) surface expression in A375-shScr and A375-
shTXNIP cells. Each open circle represents one independent experiment with biological duplicates (n = 2). 
Columns are means of three independent experiments (N = 3). Statistics: paired Student’s t-test. (G) Western 
blot analysis of tissue inhibitor of metalloproteinase-2 (TIMP-2) protein levels in total proteins extracted 
from A375-shScr and A375-shTXNIP cells; GAPDH was used as a loading control and was run on the same 
gel; triplicates (n = 3) from one experiment are shown. Cropped western blots are shown; full-length western 
blots and densitometry are shown in Supplementary Fig. 7. (H,I) Western blot analysis of Integrin beta-3 (H, 
left) and TIMP2 (I) in total proteins extracted from C8161-shScr and C8161-shTXNIP cells; Actin was used 
as loading control and was run on the same gel. Cropped western blots are shown; full-length western blots 
and densitometry are shown in Supplementary Fig. 7. (H) Right: Flow cytometry analysis of integrin alpha-v/
beta-3 (Int av/b3) surface expression in C8161-shScr and C8161-shTXNIP cells. Each open circle represents 
one independent experiment with biological duplicates (n = 2). Columns are means of three independent 
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RNA isolation and quantitative real‑time PCR (RT‑qPCR). Total RNA from cell cultures and mela-
noma tissues was isolated with TRIzol (Life Technologies) or peqGOLD TriFast (Peqlab) as per manufacturer’s 
protocol. RNA quality and integrity were assessed using a Bioanalyzer 2100 (Agilent Technologies).
0.5 to 2 μg of RNA was reverse-transcribed with random hexamers (Promega) and 200 U SuperScript II (Life 
Technologies), using the following protocol: 10 min at 25 °C, 60 min at 42 °C and 15 min at 70 °C. No-reverse-
transcriptase controls were included to check for genomic DNA contamination. cDNA relative quantity was then 
assessed by quantitative PCR using the SYBR Green detection method. Gene-specific primers: Table S6. For each 
sample, normalized relative quantities were computed using the ΔΔCt  method36.
Protein extraction, SDS‑PAGE and western blots. Proteins were extracted and separated on SDS-
PAGE as described  in7. They were transferred onto PVDF membranes (Fisher Scientific) using a semi-dry 
transfer system (Bio-Rad). Membranes were blocked with 5% BSA or 5% nonfat milk in TBST (0.05 or 0.1% 
Tween-20 in TBS, pH 7.4) for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies 
diluted in blocking buffer: anti-vinculin (1/10,000; Abcam Cat# ab129002, RRID:AB_11144129) ; anti-GAPDH 
(1:10,000;Cell Signaling Technology Cat# 2118, RRID:AB_561053); anti-TXNIP (1:1000; Santa Cruz Biotech-
nology Cat# sc-67134, RRID:AB_2210089 in all figures except Fig. 2A,B; Cell Signaling Technology Cat# 14715, 
RRID:AB_2714178 in Fig. 2A,B), anti-integrin alpha-11 (1:500; Abcam Cat# ab107858, RRID:AB_10888305), 
anti-integrin beta-3 (1:2000; Abcam Cat# ab75872, RRID:AB_2249317), anti-MMP-1 (1:500; Millipore Cat# 
IM35, RRID:AB_2282006), anti-MMP-14 (MT-MMP1; 1:500; Santa Cruz Biotechnology Cat# sc-30074, 
RRID:AB_2250767), anti-TIMP-2 (1:500, Santa Cruz Biotechnology Cat# sc-6835, RRID:AB_2204951) and 
anti-collagen alpha3(VI) (1:500; Santa Cruz Biotechnology Cat# sc-47764, RRID:AB_2083110). Membranes 
were then incubated for 1 h at room temperature with a horseradish peroxidase-conjugated goat anti-rabbit 
or -mouse secondary antibody (both 1:20,000; Promega Cat# W4011, RRID:AB_430833 and Promega Cat# 
W4021, RRID:AB_430834) in TBST with 10% blocking buffer. Western blots were revealed using enhanced 
chemiluminescence and imaged using a Fusion FX7 system (Vilber Lourmat). Densitometric analyses were done 
with BIO-1D (Vilber Lourmat).
RNA‑seq experiments. For identification of PPARγ-regulated genes, A375 cells were treated with the 
PPARγ agonist Rosiglitazone (RGZ), with the PPARγ antagonist T0070907 or a combination of both as described 
 in7. For identification of TXNIP-regulated genes, A375 were transfected with siTXNIP or siControl. Three inde-
pendent TXNIP silencing experiments were performed. In each of these 3 experiments, RNA samples from 
technical replicates of the same condition were pooled. RNA-seq experiments were conducted at the Lausanne 
Genomic Technologies Facility (Lausanne, Switzerland) according to an in-house pipeline, as described  in7.
Table 2.  Top 10 significantly downregulated (upper part) and upregulated (lower part) genes upon TXNIP 
knockdown in A375 cells, as measured by RNA-seq.
Ensembl Gene ID Gene symbol Gene name Adjusted P-value Fold change
Downregulated
ENSG00000182795 C1orf116 Chromosome 1 open reading frame 116 0.0054 −13.2
ENSG00000117289 TXNIP Thioredoxin interacting protein 0.0054 −11.0
ENSG00000143631 FLG Filaggrin 0.0061 −10.2
ENSG00000033122 LRRC7 Leucine rich repeat containing 7 0.0070 −9.3
ENSG00000163347 CLDN1 Claudin 1 0.0054 −8.0
ENSG00000182636 NDN Necdin 0.0057 −7.8
ENSG00000143473 KCNH1 Potassium channel, voltage gated eag related subfamily H, member 1 0.0058 −6.7
ENSG00000184838 PRR16 Proline rich 16 0.0061 −6.4
ENSG00000189068 VSTM1 V-set and transmembrane domain containing 1 0.0054 −6.2
ENSG00000148677 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) 0.0057 −5.9
Upregulated
ENSG00000133067 LGR6 Leucine-rich repeat containing G protein-coupled receptor 6 0.0054 18.7
ENSG00000162511 LAPTM5 Lysosomal protein transmembrane 5 0.0054 16.2
ENSG00000231574 KCCAT211 Renal clear cell carcinoma-associated transcript 211 0.011 13.2
ENSG00000229162 RP11-84D1.1 0.0057 8.2
ENSG00000187634 SAMD11 Sterile alpha motif domain containing 11 0.0057 7.9
ENSG00000163359 COL6A3 Collagen, type VI, alpha 3 0.0054 7.2
ENSG00000104435 STMN2 Stathmin 2 0.0054 6.4
ENSG00000255346 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 0.010 6.3
ENSG00000054356 PTPRN Protein tyrosine phosphatase, receptor type, N 0.0054 6.3
ENSG00000224596 ZMIZ1-AS1 ZMIZ1 antisense RNA 1 0.0054 6.0
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Microarray dataset analysis. The analyses of two melanoma microarray datasets (GSE46517 and 
GSE3189; Gene Expression Omnibus database; http:// www. ncbi. nlm. nih. gov/ geo, accessed on January  19th 
























































































































Figure 5.  TXNIP silencing affects melanoma cell adhesion and migration. (A) Trypsin resistance assays of 
A375-shScr and A375-shTXNIP cells. Each open circle represents one independent experiment with biological 
triplicates (n = 3). Columns are means of three independent experiments (N = 3). Statistics: paired Student’s 
t-test. (B) Adhesion assays of A375-shScr and A375-shTXNIP cells on various ECM protein coatings, as 
indicated. Each open circle represents one independent experiment with biological triplicates (n = 3). Except 
for Uncoated and Vitronectin treatments (N = 2), three independent experiments were performed (N = 3). 
Columns are means of two to three independent experiments. Statistics: paired Student’s t-test. (C) Adhesion 
assays of C8161-shScr and C8161-shTXNIP cells on various ECM protein coatings, as indicated. Each open 
circle represents one independent experiment with biological triplicates (n = 3). Columns are means of two to 
three independent experiments (N = 3). Statistics: paired Student’s t-test. (D) A375-shScr and A375-shTXNIP 
cell monolayer scraping assays. The quantification of three independent scraping assays (N = 3) is shown in (E) 
Grey circles/dotted line and black squares/plain line represent the means of three independent experiments 
(N = 3); each independent experiment included biological triplicates (n = 3). Data are expressed as means ± SD. 
Statistics: two-way ANOVA (F) Number of A375-shScr and A375-shTXNIP cells migrating through a porous 
membrane in a transwell assay, 6 h after plating. Each open circle represents one independent experiment with 
biological triplicates (n = 3). Columns are means of three independent experiments (N = 3). All panels *, P < 0.05; 
**, P < 0.01.
14
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7847  | https://doi.org/10.1038/s41598-021-86329-5
www.nature.com/scientificreports/
Figure 6.  TXNIP silencing favors experimental human melanoma cell seeding into the lung. (A) Pearson 
correlation plot of subcutaneous tumor growth speed  (mm3 per day) and TXNIP mRNA expression in the 
tumor at the time of tumor collection. Each circle represents one individual tumor. (B) Left panel: Whole mount 
lung quantification of tumors three weeks after intravenous injection of mCherry-labeled A375-shScr or A375-
shTXNIP cells in NSG mice. Each circle represents one individual mouse. Columns are means of individual 
samples (N = 18 mice per group). Statistics: unpaired Student’s t-test. Right panel: Representative pictures of lung 
surfaces collected three weeks after intravenous injection of mCherry-labeled A375-shScr or A375-shTXNIP in 
NSG mice (N = 18 mice per group). Scale bar: 1 mm. (C) RT-qPCR analysis of mRNA relative expression of the 
human genes B2M, MITF and MART-1 over the murine house-keeping genes Rsp9 and Eef1a1 in lungs collected 
3 weeks after intravenous injection of mCherry-labeled A375-shScr or A375-shTXNIP cells in NSG mice. Each 
open circle represents one individual mouse (N = 7 A375-shScr mice; N = 8 A375-shTXNIP mice). Columns 
represent means of individual samples. Statistics: unpaired Student’s t-test. All panels *, P < 0.05.
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RNA expression data analyses. Pre-normalized gene expression data (RPKM) as well as RECIST 
(Response Evaluation Criteria in Solid Tumors) scores were obtained from Zhang et  al. 2016 (EGA ID: 
EGAS00001000992). Samples were grouped according to their stages: Pre-treatment (stage A), On-treatment 
(stage B) and Treatment-resistant (stage C). TXNIP (ENSG00000117289) expression values where studied in the 
tumor stages using the analysis of variance method and compared using a Tukey test. TXNIP expression values 
were correlated to RECIST scores and other gene expression values (CyclinB1 ENSG00000134057; CyclinD 
ENSG00000110092; and pRb ENSG00000139687) using linear models.
In vivo experiments. All experiments involving animals were approved by the Veterinary Office of the 
Canton Vaud (Switzerland) in accordance with the Federal Swiss Veterinary Office Guidelines and conform to 
the Directive 2010/63/EU.
Subcutaneous tumor assay was performed as described  in7.
Metastatic assay: A375-shScr or A375-shTXNIP cells were injected (5 ×  106 cells) intravenously into 8 to 
10-week-old female NSG mice (IMSR Cat# JAX:001303, RRID:IMSR_JA:001303). Animals were euthanized 
3 weeks after intravenous injection. Images of whole lung were acquired using a Leica M205-FA stereo micro-
scope. mCherry fluorescent signal was quantified using ImageJ, by quantifying the intensity of the red fluo-
rescence signal normalized to the surface of the lung. The lungs were processed for total RNA extraction and 
quantification of the relative expression levels of the human genes B2M, MITF and MART over the murine 
house-keeping genes Eef1a1 and Rsp9 to evaluate the relative amount of human A375-shScr or A375-shTXNIP 
cells in the murine lungs.
Statistical analyses. Quantitative RT-qPCR results were analyzed with t tests (paired where appropriate) 
performed on log-transformed normalized relative quantities. Percent values were converted to fractions and 
log-transformed before statistical testing. Cell monolayer scraping assays were analyzed by fitting linear mod-
els relating the fraction of wound closure to time (both variables were square root-transformed); the slopes 
obtained for A375-shTXNIP and A375-shScr cells (which quantify cell migration speed) were compared 
using a F test, the null hypothesis being that they were equal. RNA-seq and microarray data were analyzed as 
described. P-values < 0.05 were considered significant. All statistical analyses were done with GraphPad Prism 
(RRID:SCR_002798 version #6).
Equipment and settings. Western blots were imaged using Fusion FX7 system (Vilber Lourmat). Images 
were saved in Compatibility Plus 16 Bit Tagged Image File Format (*.TIF) without further modification. Den-
sitometric analyses were perfomed with BIO-1D (Vilber Lourmat). Images for visual quantification of fluores-
cently labelled tumors in whole mouse lungs were acquired using Leica M205-FA stereo microscope.
Significance. Metastatic dissemination is the major cause of cancer deaths. Getting a better understanding 
of how malignant cell spread to distant organs thus remains an important issue. This study contributes to this 
critical objective by revealing a novel role for TXNIP in regulating the expression of proteins key to metastasis 
formation. Our data strongly suggests that the decrease in TXNIP that we describe in advanced melanoma biop-
sies favors melanoma cell seeding into the lung. Moreover, by identifying TXNIP as a PPARγ target, we improve 
our knowledge of the poorly characterized molecular actors involved in the functions of PPARγ in melanoma.
Data availability
RNA-seq experiments: RNAseq transcriptomic analysis of A375 human metastatic melanoma cells treated with 
the PPARγ agonist RGZ, with the PPARγ antagonist T0070907 or a combination of both is described  in7 (Pri-
mary data accession number: GSE115221). RNAseq transcriptomic analysis of A375 transfected with siTXNIP 
or siControl was submitted in excel format.
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